Abu Dhabi’s push to become a global life-sciences hub has often sounded like the usual mix of glossy renderings, free-zone incentives, and memorandums of understanding. This week, it got more concrete.
On Feb. 16, 2026 (PT), Juvenescence—a clinical-stage, AI-enabled longevity biotech—said it is establishing new research offices at Masdar City and hiring locally, alongside naming Eileen Jennings-Brown as its new Chief Technology Officer.
The announcement matters less for the org chart change (though Jennings-Brown’s résumé is notable) than for the operating model Juvenescence is describing: a company that wants to run AI-driven drug discovery while tapping Abu Dhabi’s growing constellation of genomics,
